.jpg)
Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics
Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate (ADC) space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.
Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate (ADC) space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.
